[en] Magrolimab is a first-in-class monoclonal antibody that targets and inhibits CD47, a “don’t eat me” signal overexpressed on the surface of cancer cells that allows them to evade the innate immune response. Blocking CD47 leads to increased recognition and phagocytosis of cancer cells. Since its initial description and promising data in pre-clinical and clinical studies, three phase III studies investigating magrolimab in AML patients are ongoing in Belgium and worldwide.
Disciplines :
Hematology
Author, co-author :
De Voeght, Adrien ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'hématologie clinique
